Yan Chen
Aab Cardiovascular Research Institute, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, U.S.A.
Clin Sci (Lond). 2015 Dec;129(12):1077-81. doi: 10.1042/CS20150605. Epub 2015 Sep 15.
VSMCs (vascular smooth muscle cells) play critical roles in arterial remodelling with aging, hypertension and atherosclerosis. VSMCs exist in diverse phenotypes and exhibit phenotypic plasticity, e.g. changing from a quiescent/contractile phenotype to an active myofibroblast-like, often called 'synthetic', phenotype. Synthetic VSMCs are able to proliferate, migrate and secrete ECM (extracellular matrix) proteinases and ECM proteins. In addition, they produce pro-inflammatory molecules, providing an inflammatory microenvironment for leucocyte penetration, accumulation and activation. The aging VSMCs have also shown changes in cellular phenotype, responsiveness to contracting and relaxing mediators, replicating potential, matrix synthesis, inflammatory mediators and intracellular signalling. VSMC dysfunction plays a key role in age-associated vascular remodelling. Cyclic nucleotide PDEs (phosphodiesterases), by catalysing cyclic nucleotide hydrolysis, play a critical role in regulating the amplitude, duration and compartmentalization of cyclic nucleotide signalling. Abnormal alterations of PDEs and subsequent changes in cyclic nucleotide homoeostasis have been implicated in a number of different diseases. In the study published in the latest issue of Clinical Science, Bautista Niño and colleagues have shown that, in cultured senescent human VSMCs, PDE1A and PDE1C mRNA levels are significantly up-regulated and inhibition of PDE1 activity with vinpocetine reduced cellular senescent makers in senescent VSMCs. Moreover, in the premature aging mice with genomic instability (Ercc1(d/-)), impaired aortic ring relaxation in response to SNP (sodium nitroprusside), an NO (nitric oxide) donor, was also largely improved by vinpocetine. More interestingly, using data from human GWAS (genome-wide association studies), it has been found that PDE1A single nucleotide polymorphisms is significantly associated with diastolic blood pressure and carotid intima-media thickening, two hallmarks of human vascular dysfunction in aging. These findings establish a strong relationship between PDE1 expression regulation and vascular abnormalities in aging.
血管平滑肌细胞(VSMCs)在衰老、高血压和动脉粥样硬化引起的动脉重塑过程中发挥着关键作用。血管平滑肌细胞具有多种表型,并表现出表型可塑性,例如从静止/收缩表型转变为活跃的成肌纤维细胞样表型,这种表型通常被称为“合成”表型。合成型血管平滑肌细胞能够增殖、迁移并分泌细胞外基质(ECM)蛋白酶和ECM蛋白。此外,它们还会产生促炎分子,为白细胞的渗透、聚集和激活提供炎症微环境。衰老的血管平滑肌细胞在细胞表型、对收缩和舒张介质的反应性、复制潜能、基质合成、炎症介质以及细胞内信号传导等方面也表现出变化。血管平滑肌细胞功能障碍在与年龄相关的血管重塑中起关键作用。环核苷酸磷酸二酯酶(PDEs)通过催化环核苷酸水解,在调节环核苷酸信号传导的幅度、持续时间和区域化方面发挥着关键作用。磷酸二酯酶的异常改变以及随后环核苷酸稳态的变化与多种不同疾病有关。在最新一期《临床科学》杂志上发表的一项研究中,包蒂斯塔·尼尼奥及其同事表明,在培养的衰老人类血管平滑肌细胞中,PDE1A和PDE1C的mRNA水平显著上调,而用长春西汀抑制PDE1活性可降低衰老血管平滑肌细胞中的细胞衰老标志物。此外,在具有基因组不稳定性的早衰小鼠(Ercc1(d/-))中,长春西汀也在很大程度上改善了主动脉环对一氧化氮(NO)供体硝普钠(SNP)反应时的舒张功能受损情况。更有趣的是,通过使用来自人类全基因组关联研究(GWAS)的数据发现,PDE1A单核苷酸多态性与舒张压和颈动脉内膜中层增厚显著相关,这是人类衰老过程中血管功能障碍的两个标志。这些发现确立了PDE1表达调控与衰老过程中血管异常之间的紧密关系。